RECEPTORS OF VESSEL ENDOTHELIAL GROWTH FACTOR 1 AND 2 TYPE AT SIGNIFICANT INTERLEUKIN-16 LEVELS IN THE SERUM OF THE BLOOD OF PATIENTS WITH BONE NEOPLASMS

DOI: https://doi.org/10.29296/25877313-2019-06-06
Download full text PDF
Issue: 
6
Year: 
2019

I.V. Babkina Dr.Sc. (Med.), Professor, Department of Clinical Biochemistry and Laboratory Diagnostics, A.I. Evdokimov Moscow State Medical and Dental University of the Ministry of Health of Russia (Moscow) E-mail: docbabkina@rambler.ru E.S. Gershtein Dr.Sc. (Biol.), Professor N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia (Moscow) A.V. Bondarev Oncologist, Moscow Oncological Hospital № 62 (Moscow) Yu.N. Soloviev Dr.Sc. (Med.), Professor, Academician of RAS, N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia (Moscow) I.V. Boulitcheva Dr.Sc. (Med.), Pathologist, N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia (Moscow) I.S. Chernomaz Post-graduate Student, Department of Clinical Biochemistry and Laboratory Diagnostics, A.I. Evdokimov Moscow State Medical and Dental University of the Ministry of Health of Russia (Moscow) Yu.M. Shchupak Oncologist, Head of Surgical Department, Moscow Oncological Hospital № 62 (Moscow) M.D. Aliev Dr.Sc. (Med.), Professor, Academician of RAS, N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia (Moscow) N.E. Kushlinskii Dr.Sc. (Med.), Professor, Correspondent Member of RAS, N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia (Moscow)

Relevance. The results of molecular biological studies served as the basis for conducting a clinical study on the possibility of using antiangio-genic drugs in the treatment of bone sarcomas. Their mechanism of action is to inhibit tyrosine kinases involved in tumor growth, including inhibiting the binding of a key activator of neoangiogenesis of vascular endothelial growth factor (VEGF) with its type 1 and 2 receptors (VEGFR1, VEGFR2), which leads to a decrease in vascularization and inhibition tumor growth. In addition to VEGF, other biologically active substances, including the interleukin-16 cytokine (IL-16), are also involved in tumor neoangiogenesis activators. Goal. Сomparative study of the initial levels of VEGFR1 and VEGFR2 receptors in the serum of patients with malignant, borderline and benign bone neoplasms with significant levels of IL-16 and their role in the bone sarcomas prognosis. Material and methods. We examined 138 patients with bone tumors (malignant  106; benign - 10; borderline (giant cell tumor) - 22). The markers were studied by an enzyme immunoassay method in the blood serum of patients before the specific treatment with Biosource (USA) reagents - IL-16 and “R & D” (USA) - VEGFR1 and VEGFR2. Statistical processing of the results was performed using the program "Statistica 7.0". Results. Significant levels of IL-16 were detected in serum samples of 93% of patients with bone neoplasms. Differences in the content of IL-16 in the serum with regard to the morphological structure of the tumor was not detected. In typical osteosarcoma and Ewing's sarcoma, serum lev-els of VEGFR1 and VEGFR2 are significantly higher than in chondrosarcoma (p = 0.0003 and p = 0.00009; and p = 0.032 and p = 0.005, respectively). The serum levels of VEGFR1 and VEGFR2 in patients with bone tumors were significantly higher at baseline levels of IL-16 ≤33.0 pg / ml than in pa-tients with high levels of IL-16 > 33.0 pg / ml (p = 0.027 and p = 0.026 respectively). A significant direct relationship was found between serum levels of VEGFR1 and VEGFR2 (r = 0.34, p = 0.002). The overall 5-year survival in the entire group was 56%. The overall 5-year survival in the entire group was 56%. With a combination of IL-16 ≤33 pg / ml and VEGFR2 33 pg / ml and low VEGFR2 < 11.3 ng / ml - it was equal to 25%. The overall 5-year survival rate in the presence of all high values of IL-16, VEGFR1, VEGFR2 in the blood was 67%, for all low values of marker - 78%. It should be noted that with a combination of levels of IL-16> 33.0 pg / ml, VEGFR1

Keywords: 
IL-16
VEGFR1
VEGFR2
bone sarcomas
overall survival

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Grignani G., Palmerini E., Dileo P., Asaftei S.D., D'Ambrosio L., Pignochino Y., Mercuri M., Picci P., Fagioli F., Casali P.G., Ferrari S., Aglietta M. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study // Ann. Oncol. 2012; 23(2):508-516.
  2. Raciborska A., Bilska K. Sorafenib in patients with progressed and refractory bone tumors // Med. Oncol. 2018; 35(10):126.
  3. Glade Bender J.L., Lee A., Reid J.M., Baruchel S., Roberts T., Voss S.D., Wu B., Ahern C.H., Ingle A.M., Harris P., Weigel B.J., Blaney S.M. Phase I pharmacokinetic and pharmacodynamics study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children’s oncology group Phase I consortium report // J. Clin. Oncol. 2013;31(24): 3034-3043.
  4. Mori Y., Kinoshita S., Kanamori T., Kataoka H., Joh T., Iida S., Takemoto M., Kondo M., Kuroda J., Komatsu H. The Successful Treatment of Metastatic Extraosseous Ewing Sarcoma with Pazopanib // Intern. Med. 2018; 57(18): 2753-2757.
  5. Fox E., Aplenc R., Bagatell R., Chuk M.K., Dombi E., Goodspeed W., Goodwin A., Kromplewski M., Jayaprakash N., Marotti M., Brown K.H., Wenrich B., Adamson P.C., Widemann B.C., Balis F.M. A phase I trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor inhibitor, in children and adolescents with refractory solid tumors // J. Clin. Oncol. 2010; 28(35): 5174-5181.
  6. van Cruijsen H., Voest E.E., Punt C.J., Hoekman K., Witteveen P.O., Meijerink M.R., Puchalski T.A., Robertson J., Saunders O., Jürgensmeier J.M., van Herpen C.M., Giaccone G. Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours // Eur. J. Cancer. 2010; 46(5):901-911.
  7. Dubois S.G., Shsterman S., Ingle A.M. Ahern C.H., Reid J.M., Wu B., Baruchel S., Glade-Bender J., Ivy P., Grier H.E., Adamson P.C., Blaney S.M. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children’s oncology group study // Clin. Cancer. Res. 2011; 17:5113-5122.
  8. Versleijen-Jonkers Y.M., Vlenterie M., van de Luijtgaarden A.C., van der Graaf W.T. Anti-angiogenic therapy, a new player in the field of sarcoma treatment // Crit. Rev. Oncol. Hematol. 2014:91(2): 172-185.
  9. Sia D., Alsinet C., Newell P., Villanueva A. VEGF signaling in cancer treatment // Curr. Pharm. Des. 2014; 20(17):2834-2842.
  10. Yellapa A., Bitterman P., Sharma S., Guirguis A.S., Bahr J.M., Basu S., Abramowicz J.S., Barua A. Interleukin 16 expression changes in association with ovarian malignant transformation // Am. J. Obstet. Gynecol. 2014; 210(3):272.e1-10.
  11. Tang Y.J., Wang J.L., Xie K.G., Lan C.G. Association of interleukin 16 gene polymorphisms and plasma IL16 level with osteosarcoma risk // Sci. Rep. 2016; 6:34607.
  12. Babkina I.V., Bondarev A.V., Schupak M.Ju., Kuznetsov I.N., Solov'ev Ju.N., Aliev M.D., Kushlinskij N.E. Perspektivy issledovanija interlejkina-16 i faktora rosta endotelija sosudov u bol'nyh opuholjami kostej // Sarkomy kostej, mjagkih tkanej i kozhi. 2015; 2:23-30. (Babkina I.V., Bondarev A.V., Shchupak M.Yu., Kuznecov I.N., Soloviev Yu.N., Aliev M.D., Kushlinskii N.E. Perspektivy issledovaniya interlejkina-16 i faktora rosta endoteliya sosudov u bol'nyh opuholyami kostej // Sarkomy kostej, myagkih tkanej i kozhi. 2015; 2:23-30)